Can Immunity to Breast Cancer Eliminate Residual Micrometastases?
暂无分享,去创建一个
[1] M. Ellis,et al. Incorporating Genomics into Breast Cancer Clinical Trials and Care , 2013, Clinical Cancer Research.
[2] J. Baselga,et al. Neoadjuvant Therapy as a Platform for Drug Development and Approval in Breast Cancer , 2013, Clinical Cancer Research.
[3] Hailing Lu,et al. The Invisible Arm of Immunity in Common Cancer Chemoprevention Agents , 2013, Cancer Prevention Research.
[4] J. Bergh,et al. Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis , 2013, Genome Biology.
[5] K. Schäkel,et al. Impact of chemotherapeutic agents on the immunostimulatory properties of human 6‐sulfo LacNAc+ (slan) dendritic cells , 2013, International journal of cancer.
[6] E. Jaffee,et al. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. , 2012, Cancer research.
[7] A. Stojadinovic,et al. Clinical trial results of the HER‐2/neu (E75) vaccine to prevent breast cancer recurrence in high‐risk patients , 2012, Cancer.
[8] D. Matei,et al. Abstract 3439: Tissue tranglutaminase (TG2) targeting by multifunctional field responsive gold nanoparticles , 2012 .
[9] C. Sautès-Fridman,et al. The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.
[10] L. Zitvogel,et al. The secret ally: immunostimulation by anticancer drugs , 2012, Nature Reviews Drug Discovery.
[11] David Haussler,et al. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling , 2011, Proceedings of the National Academy of Sciences.
[12] P. Fumoleau,et al. T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival , 2011, British Journal of Cancer.
[13] D. Yin,et al. CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes , 2011, Breast Cancer Research and Treatment.
[14] Xiaoling Hu,et al. TNFα Cooperates with IFN-γ to Repress Bcl-xL Expression to Sensitize Metastatic Colon Carcinoma Cells to TRAIL-mediated Apoptosis , 2011, PLoS ONE.
[15] Lajos Pusztai,et al. A clinically relevant gene signature in triple negative and basal-like breast cancer , 2010, Breast Cancer Research.
[16] P. Gattuso,et al. Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: Role of uric acid accumulation in gemcitabine-induced MICA/B expression , 2011, BMC Cancer.
[17] M. Disis. Immune regulation of cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Soldano Ferrone,et al. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] M. Greene,et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. , 2010, Cancer cell.
[20] Johan Staaf,et al. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] S. Altiok,et al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. , 2010, The Journal of clinical investigation.
[22] Carsten Denkert,et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] J. Waisman,et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] R. Coombes,et al. The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer , 2009, British Journal of Cancer.
[25] Ping Zhang,et al. Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. , 2008, Molecular immunology.
[26] J. Waisman,et al. Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity , 2008, Molecular Cancer Therapeutics.
[27] D. Petrylak,et al. Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy , 2007, Clinical Cancer Research.
[28] H. Nisenbaum,et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. , 2007, Cancer research.
[29] F. Penault-Llorca,et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? , 2006, British Journal of Cancer.